Ranbaxy Also Could Face Probe By Indian Authorities
This article was originally published in PharmAsia News
Executive SummaryRanbaxy Laboratories not only faces an investigation in the U.S., it also could become the subject of a probe at home in India. Indian authorities have raised questions about whether Ranbaxy's stockholders were informed about U.S. FDA allegations that the firm marketed adulterated generics. Indian authorities are expected to review the same documents requested by U.S. authorities, to see if the company adequately informed shareholders of the financial risks involved in the investigation. (Click here for more
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.